Trial Design: Adjuvant MK-6482-022
Pembro + MK-6482 vs. Pembro + PO Placebo (MK-6482)

Key Inclusion Criteria

- Histologically confirmed diagnosis of **ccRCC**
- No prior systemic therapy
- ECOG PS 0 or 1
- Participants must be randomized ≤12 weeks after surgery
- **BICR-confirmed** tumor-free (CT or MRI) of brain, chest, abdomen, pelvis and bone scan

Population

Intermediate-high risk
- pT2, Gr. 4, N0, M0
- pT3, Any Gr., N0, M0

High Risk RCC
- pT4, Any Gr. N0, M0
- pT Any stage, Any Gr., N+, M0

M1 NED

1:1

N: ~1,600

Belzutifan (120 mg QD 12 mo) + Pembro (400 mg Q6W x 9 cycles)

PO Placebo (12 mo) + Pembro (400 mg Q6W x 9 cycles) (n=800)

Primary Endpoint
- DFS by BICR

Key Secondary Endpoint
- OS

MSD INVENTING FOR LIFE